Pfizer Limited convened a Board of Directors meeting on September 7, 2026, with the outcome communicated to NSE at 11:25 AM, according to a regulatory filing submitted by the Mumbai-headquartered pharmaceutical major. The announcement did not disclose specific resolutions passed, but given the company's established practice of declaring dividends in the September quarter, investors are closely watching for a payout decision consistent with prior years.

Dividend History and Trend Analysis

Pfizer India has maintained a consistent, and at times elevated, dividend distribution record over the past eight financial years. The per-share payouts are as follows:

Excluding one-time special payouts tied to asset sales, the recurring annual dividend has held steady in the ₹30 to ₹35 per share range between FY2021 and FY2024, indicating a stable and predictable distribution policy. The FY2023 special dividend of ₹5 per share was explicitly linked to a gain on the sale of the company's Thane business undertaking and is not considered part of the recurring payout pattern.

Dividend Yield Context

With no live trade data available at the time of this publication, a precise real-time yield calculation cannot be provided. However, based on Pfizer India's most recent disclosed annual dividend of ₹35 per share for FY2024, investors can compute the yield against the prevailing market price. Pfizer India trades on the NSE under the symbol PFIZER with ISIN INE182A01018. Given that the stock has historically traded in a range that places its dividend yield well below the sector median, the company's appeal among income investors is complemented by its strong parentage and balance sheet quality rather than yield alone.

Company Background

Pfizer Limited is the Indian subsidiary of Pfizer Inc., one of the world's largest pharmaceutical corporations. The company operates across therapeutic segments including anti-infectives, cardiovascular, pain management, and vaccines. Its Indian business has undergone significant restructuring in recent years, including the sale of the Thane manufacturing facility, which generated the special dividend in FY2023.

What This Means for Investors

The September 7, 2026 board meeting follows the same calendar pattern as the September 2022 interim dividend declaration, when the board announced a ₹30 per share payout. Investors should note that Pfizer India has historically used both May and September board meetings to declare dividends, suggesting the possibility of a payout announcement from this meeting. The full outcome disclosure will determine whether a dividend, interim or otherwise, has been recommended. Shareholders are advised to monitor the official NSE filing portal for the complete board meeting outcome. No trade data, delivery percentage, or 52-week price range was available at the time of this report to complete market-specific calculations.